CSL shares dip despite new FDA approval

What's with CSL today?

| More on:
A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL shares are falling slightly on the ASX 200 today 
  • The ASX 200 Healthcare Index is also sliding today 
  • CSL has received FDA approval for a 50mL prefilled syringe product

The CSL Ltd (ASX: CSL) share price is slightly in the red today despite some positive news from the company.

CSL shares are sliding 0.34% and are currently fetching $299.22. For perspective, the S&P/ASX 200 Health Care Index (ASX: XHJ) is sliding 0.25% today.

Let's take a look at what is going on with CSL today.

FDA approval for Hizentra

CSL is not the only ASX healthcare share in the red today. Ramsay Health Care Ltd (ASX: RHC) shares are down 0.7%, Pro Medicus Ltd (ASX: PME) shares are sliding 0.18%, and Resmed Inc (ASX: RMD) shares are down 0.48%.

In news out of the company, CSL Behring today advised the U.S. Food and Drug Administration (FDA) has approved a 50mL/10gm prefilled syringe for Hizentra.

Hizentra is the only immune globulin (Ig) that is accessible in a convenient ready-to-use prefilled syringe.

The 50mL syringe will be available in early 2024, providing the company with time to provide enough supply to meet demand.

This will help people with Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

Hizentra will still be available in 5mL, 10mL, and 20mL prefilled syringes and 5mL, 10mL, 20mL, and 50mL vials in the meantime.

Commenting on the news, CSL Behring senior vice president and general manager for North America Bob Lojewski said:

We are proud to be at the forefront of delivering effective treatment options that also provide flexibility by allowing those with PI or CIDP to self-administer their treatments based on their specific needs and lifestyles.

As part of our promise to meet the needs of people who rely on our life-saving therapies, we recognize the important value of offering people with PI or CIDP a larger prefilled syringe size option to effectively manage their condition

As my Foolish colleague James reported today, multiple brokers are positive on the CSL share price going forward. Citi, Macquarie and Morgans all have a "buy" rating on CSL. Citi has a $350 price target on the company's share price, Macquarie forecasts CSL to hit $344 and Morgans has a $337.92 prediction for CSL. This is all significant upside on CSL's current share price.

Share price snapshot

CSL shares have gained 13.68% in the last year.

CSL has a market cap of about $143.9 billion based on the current share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Pro Medicus, and ResMed. The Motley Fool Australia has positions in and has recommended Pro Medicus and ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »